股本结构
单位：万股
| 公告日期 | 2025-12-12 | 2025-11-14 | 2025-10-23 | 2025-09-29 | 2025-09-24 | 2025-08-14 |
|---|---|---|---|---|---|---|
| 证券总股本 | 102.34 | 59.70 | 51.83 | 621.96 | 507.96 | 324.63 |
| 普通股本 | 102.34 | 59.70 | 51.83 | 621.96 | 507.96 | 324.63 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-12-12 | 2025-11-12 | 2025-10-28 | 2025-09-25 | 2025-09-18 | 2025-08-13 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-12-12 | 102.34 | 未披露 |
更多>>
The underwriter exercised the warrants to cause the company to issue 426,390 shares of common stock
|
2025-12-12 |
| 2025-11-14 | 59.70 | 未披露 | 定期报告 | 2025-11-12 |
| 2025-10-23 | 51.83 | 未披露 |
更多>>
a 1-for-12 reverse stock split of the Company's common stock
|
2025-10-28 |
| 2025-09-29 | 621.96 | 未披露 | 定期报告 | 2025-09-25 |
| 2025-09-24 | 507.96 | 未披露 | 定期报告 | 2025-09-18 |
| 2025-08-14 | 324.63 | 未披露 | 定期报告 | 2025-08-13 |
| 2025-08-14 | 302.60 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $179,714
|
2025-06-30 |
| 2025-05-14 | 247.17 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of common stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487
Issuance of common shares for vested RSAs
Issuance of common shares for exercise of warrants
Issuance of round up shares
|
2025-03-31 |
| 2025-03-28 | 247.17 | 未披露 | 定期报告 | 2025-03-27 |
| 2025-02-03 | 192.19 | 未披露 |
更多>>
Common Stock offered 1,229,330 shares by the company
|
2025-02-03 |
| 2025-01-21 | 69.26 | 未披露 |
更多>>
a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock
|
2025-01-29 |
| 2025-01-14 | 1038.87 | 未披露 | 定期报告 | 2025-01-10 |
| 2024-12-18 | 1016.99 | 未披露 | 定期报告 | 2024-12-11 |
| 2024-11-14 | 994.49 | 未披露 | 定期报告 | 2024-11-12 |
| 2024-11-14 | 899.49 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Common stock sold under the Purchase Agreement, net of offering costs of $290,029
Issuance of common shares for vested RSU
|
2024-09-30 |
| 2024-09-12 | 891.99 | 未披露 | 定期报告 | 2024-08-30 |
| 2024-08-12 | 891.99 | 未披露 | 定期报告 | 2024-08-09 |
| 2024-07-08 | 795.36 | 未披露 | 定期报告 | 2024-07-05 |
| 2024-08-12 | 787.86 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of direct offering shares
Issuance of common shares for vested RSU
Common stock sold under the Purchase Agreement, net of offering costs of $82,850
|
2024-06-30 |
| 2024-05-03 | 775.20 | 未披露 |
更多>>
Common stock offered 458,000 shares by the company
|
2024-05-06 |
| 2024-05-15 | 729.40 | 未披露 |
更多>>
From January 1, 2024 to March 31, 2024
Common stock sold under the Equity Distribution Agreement, net of offering costs of $583,713
Issuance of direct offering shares
Exercise of Inducement Warrants for common stock
Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance
|
2024-03-31 |
| 2024-03-26 | 729.40 | 未披露 | 定期报告 | 2024-03-21 |
| 2024-03-11 | 562.60 | 未披露 |
更多>>
Common stock offered 228,690 shares by the company
|
2024-03-12 |
| 2024-03-11 | 539.73 | 未披露 | 定期报告 | 2024-03-11 |
| 2024-03-26 | 273.93 | 未披露 |
更多>>
From January 1, 2023 to December 31, 2023
Issuance of common shares for deferred offering costs
Issuance of common shares in exchange for RSU conversions
Exercise of warrants and preferred investment options
|
2023-12-31 |
| 2023-11-13 | 232.13 | 未披露 | 定期报告 | 2023-11-09 |
| 2023-11-13 | 218.19 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common shares in exchange for RSU conversions
|
2023-09-30 |
| 2023-09-01 | 218.19 | 未披露 | 定期报告 | 2023-08-30 |
| 2023-08-11 | 214.79 | 未披露 | 定期报告 | 2023-08-09 |
| 2023-08-11 | 214.18 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common shares in exchange for RSU conversions from the reduction in force
|
2023-06-30 |
| 2023-05-15 | 207.83 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-03-31 | 207.83 | 5.27 |
更多>>
From January 1,2022 to December 31, 2022
Issuance of redeemable Series C preferred stock
Redemption of Series C preferred stock
February 2022 registered direct offering, net of offering costs
Stock-based compensation
Conversion of RSUs into common shares
Conversion of RSAs into common shares
July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs
Issuance of rounded shares as a result of the reverse stock split
|
2022-12-31 |
| 2022-11-14 | 207.83 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs
Issuance of rounded shares as a result of the reverse stock split
Redemption of Series C preferred stock
|
2022-09-30 |
| 2022-09-23 | 207.83 | 未披露 | 定期报告 | 2022-09-14 |
| 2022-08-12 | 157.48 | 未披露 | 定期报告 | 2022-08-11 |
| 2022-08-05 | 155.40 | 未披露 | 定期报告 | 2022-08-04 |
| 2022-07-26 | 142.90 | 未披露 |
更多>>
1.Common stock offered by 116,500 shares of common stock
2.Unless otherwise indicated, the number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 1,054,043 shares outstanding as of July 21, 2022
|
2022-07-26 |
| 2022-07-26 | 105.40 | 未披露 | 定期报告 | 2022-07-21 |
| 2022-07-14 | 105.37 | 未披露 |
更多>>
Enveric Biosciences, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022.
|
2022-07-15 |
| 2022-05-31 | 5268.45 | 5.27 | 定期报告 | 2022-05-19 |
| 2022-05-13 | 5268.45 | 未披露 | 定期报告 | 2022-05-11 |
| 2022-05-13 | 5262.34 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
February 2022 registered direct offering
Conversion of RSUs into common shares
|
2022-03-31 |
| 2022-03-31 | 5258.51 | 未披露 | 定期报告 | 2022-03-30 |
| 2022-02-11 | 3257.85 | 未披露 | 定期报告 | 2022-02-08 |
| 2022-03-31 | 3257.85 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Conversion of Series B preferred shares
January 2021 registered direct offering
February 2021 registered direct offering
Consideration paid pursuant to amalgamation agreement
Warrant exercise
Cashless options exercise
Induced conversion of warrants and options to Common Stock
Common stock issued in lieu of cash for services
Common stock issued pursuant to exercise of warrant put rights
|
2021-12-31 |
| 2021-11-15 | 3138.36 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Consideration paid pursuant to amalgamation agreement
|
2021-09-30 |
| 2021-08-13 | 2143.24 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Stock based compensation
Conversion of stock options into restricted stock
Exercise of warrants
Exercise of options
|
2021-06-30 |
| 2021-05-20 | 2139.03 | 未披露 | 定期报告 | 2021-05-13 |
| 2021-04-13 | 2188.22 | 未披露 | 定期报告 | 2021-04-08 |
| 2021-05-17 | 1945.00 | 未披露 |
更多>>
From January 1, 2021 To March 31, 2021
Conversion of Series B Preferred Stock
January 2021 registered direct offering
February 2021 registered direct offering
Exercise of warrants
|
2021-03-31 |
| 2021-04-01 | 1945.05 | 未披露 | 定期报告 | 2021-03-29 |
| 2021-04-13 | 1945.00 | 未披露 | 定期报告 | 2021-03-17 |
| 2021-02-11 | 1833.64 | 未披露 |
更多>>
1.Common Stock offered by the company 3,007,026 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 15,329,350 shares outstanding as of February 9, 2021.
|
2021-02-11 |
| 2021-02-11 | 1532.94 | 未披露 | 定期报告 | 2021-02-09 |
| 2021-01-14 | 1381.65 | 未披露 |
更多>>
1.Common Stock offered by the company 1,610,679 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 11,595,109 shares outstanding as of January 12, 2021.
|
2021-01-14 |
| 2021-01-13 | 1159.51 | 177.54 | 定期报告 | 2021-01-12 |
| 2021-04-01 | 1009.51 | 327.54 |
更多>>
from January 1, 2020 to December 31, 2020
December 2020 private placement
Alpha financing and conversion of Alpha Note, including Palladium shares
Conversion of Series B preferred stock to common stock
September 2020 private placement
Acquisition of Tikkun Pharma IP
Exchange of warrants for common shares
Conversion of related party advance and notes payable
Common stock issued for accounts payable
Common stock issued in conjunction with note payable modification
Merger with Ameri Holdings, Inc.
|
2020-12-31 |
| 2020-11-16 | 749.15 | 未披露 | 定期报告 | 2020-11-13 |
| 2020-11-13 | 744.13 | 未披露 | 定期报告 | 2020-11-11 |
| 2020-11-04 | 667.16 | 未披露 | 定期报告 | 2020-10-30 |
| 2020-10-22 | 647.01 | 未披露 | 定期报告 | 2020-10-21 |
| 2020-11-16 | 573.70 | 42.49 |
更多>>
From December 31, 2019 to August 11, 2020
Shares Issued for Extinguishment of liability
Rights Issue of Shares
|
2020-08-11 |
| 2020-08-04 | 578.99 | 未披露 |
更多>>
1.Common stock offered 373,766 shares.
|
2020-08-04 |
| 2020-08-14 | 516.33 | 42.49 |
更多>>
From December 31, 2019 to June 30, 2020
Shares Issued for Extinguishment of liability
Rights Issue of Shares
|
2020-06-30 |
| 2020-06-04 | 453.47 | 未披露 |
更多>>
1.Common stock offered 862,500 shares.
|
2020-06-04 |
| 2020-05-15 | 324.67 | 42.49 |
更多>>
From December 31, 2019 to March 31, 2020
Shares Issued for Extinguishment of liability
Conversion of accrued Interest
|
2020-03-31 |
| 2020-03-25 | 324.67 | 未披露 | 定期报告 | 2020-03-22 |
| 2020-03-25 | 252.21 | 42.49 |
更多>>
From December 31, 2018 to December 31, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A&B)
Shares issued for Fraction shares on reverse split
Preferred stock issued
|
2019-12-31 |
| 2019-11-25 | 251.28 | 未披露 |
更多>>
On November 8, 2019, a majority of the company’s stockholders approved giving the Board discretionary authority to enact the reverse stock split. The Board approved the reverse stock split on a one for twenty-five ratio on November 21, 2019.
|
2019-11-25 |
| 2019-11-08 | 6282.08 | 42.49 |
更多>>
from June 30, 2019 to September 30, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A&B)
Preferred stock issued
|
2019-09-30 |
| 2019-09-27 | 6282.08 | 未披露 | 定期报告 | 2019-09-19 |
| 2019-08-14 | 5241.77 | 42.49 |
更多>>
From December 31, 2018 to June 30, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A)
Preferred stock issued
|
2019-06-30 |
| 2019-05-14 | 5031.77 | 未披露 | 定期报告 | 2019-05-03 |
| 2019-04-30 | 5048.67 | 未披露 | 定期报告 | 2019-04-22 |
| 2019-05-14 | 5031.77 | 42.07 |
更多>>
from December 31, 2018 to March 31, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A)
|
2019-03-31 |
| 2019-03-26 | 4702.84 | 未披露 | 定期报告 | 2019-03-22 |
| 2019-03-26 | 4232.91 | 42.07 |
更多>>
from December 31, 2017 to December 31, 2018
Shares issued towards private placement
Exercise of warrants
Shares Issued towards earn-outs
Compensation to Directors
Compensation on seperation
Shares issued against preference dividend
Shares issued as acquisition consideration
|
2018-12-31 |
| 2018-11-14 | 3960.76 | 未披露 | 定期报告 | 2018-11-08 |
| 2018-11-14 | 2294.60 | 41.86 | 定期报告 | 2018-09-30 |
| 2018-08-24 | 1906.34 | 未披露 | 定期报告 | 2018-08-24 |
| 2018-08-22 | 2287.34 | 41.86 | 定期报告 | 2018-08-20 |
| 2018-08-14 | 2287.34 | 未披露 | 定期报告 | 2018-08-08 |
| 2018-08-14 | 1901.24 | 40.54 | 定期报告 | 2018-06-30 |
| 2018-05-15 | 1879.10 | 未披露 | 定期报告 | 2018-05-08 |
| 2018-04-30 | 2011.29 | 未披露 | 定期报告 | 2018-04-27 |
| 2018-05-15 | 1879.10 | 40.54 | 定期报告 | 2018-03-31 |
| 2018-04-02 | 1879.10 | 未披露 | 定期报告 | 2018-03-29 |
| 2018-04-02 | 1816.27 | 40.54 |
更多>>
from December 31, 2016 to December 31, 2017
Shares issued against services
Shares issued as acquisition consideration (ATCG)
Exercise and acceleration of RSU’s
Bonus shares issued to employees and Directors
Shares Issued towards earn-outs
Cashless exercise of warrants
Public offering of shares
Shares issued against preference dividend
|
2017-12-31 |
| 2017-11-20 | 1733.12 | 未披露 |
更多>>
1.Common stock offered by us 1,475,000 shares
2.Based on 15,856,249 shares outstanding on November 10, 2017
|
2017-11-17 |
| 2017-11-13 | 1585.62 | 38.40 | 定期报告 | 2017-09-30 |
| 2017-09-18 | 1465.04 | 37.37 | 定期报告 | 2017-06-30 |
The underwriter exercised the warrants to cause the company to issue 426,390 shares of common stock
a 1-for-12 reverse stock split of the Company's common stock
From March 31, 2025 to June 30, 2025
Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $179,714
From January 1, 2025 to March 31, 2025
Issuance of common stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487
Issuance of common shares for vested RSAs
Issuance of common shares for exercise of warrants
Issuance of round up shares
Common Stock offered 1,229,330 shares by the company
a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock
From June 30, 2024 to September 30, 2024
Common stock sold under the Purchase Agreement, net of offering costs of $290,029
Issuance of common shares for vested RSU
From March 31, 2024 to June 30, 2024
Issuance of direct offering shares
Issuance of common shares for vested RSU
Common stock sold under the Purchase Agreement, net of offering costs of $82,850
Common stock offered 458,000 shares by the company
From January 1, 2024 to March 31, 2024
Common stock sold under the Equity Distribution Agreement, net of offering costs of $583,713
Issuance of direct offering shares
Exercise of Inducement Warrants for common stock
Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance
Common stock offered 228,690 shares by the company
From January 1, 2023 to December 31, 2023
Issuance of common shares for deferred offering costs
Issuance of common shares in exchange for RSU conversions
Exercise of warrants and preferred investment options
From June 30, 2023 to September 30, 2023
Issuance of common shares in exchange for RSU conversions
From March 31, 2023 to June 30, 2023
Issuance of common shares in exchange for RSU conversions from the reduction in force
From January 1,2022 to December 31, 2022
Issuance of redeemable Series C preferred stock
Redemption of Series C preferred stock
February 2022 registered direct offering, net of offering costs
Stock-based compensation
Conversion of RSUs into common shares
Conversion of RSAs into common shares
July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs
Issuance of rounded shares as a result of the reverse stock split
From June 30, 2022 to September 30, 2022
July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs
Issuance of rounded shares as a result of the reverse stock split
Redemption of Series C preferred stock
1.Common stock offered by 116,500 shares of common stock
2.Unless otherwise indicated, the number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 1,054,043 shares outstanding as of July 21, 2022
Enveric Biosciences, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022.
From January 1, 2022 to March 31, 2022
February 2022 registered direct offering
Conversion of RSUs into common shares
From December 31, 2020 to December 31, 2021
Conversion of Series B preferred shares
January 2021 registered direct offering
February 2021 registered direct offering
Consideration paid pursuant to amalgamation agreement
Warrant exercise
Cashless options exercise
Induced conversion of warrants and options to Common Stock
Common stock issued in lieu of cash for services
Common stock issued pursuant to exercise of warrant put rights
From June 30, 2021 to September 30, 2021
Consideration paid pursuant to amalgamation agreement
From March 31, 2021 to June 30, 2021
Stock based compensation
Conversion of stock options into restricted stock
Exercise of warrants
Exercise of options
From January 1, 2021 To March 31, 2021
Conversion of Series B Preferred Stock
January 2021 registered direct offering
February 2021 registered direct offering
Exercise of warrants
1.Common Stock offered by the company 3,007,026 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 15,329,350 shares outstanding as of February 9, 2021.
1.Common Stock offered by the company 1,610,679 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 11,595,109 shares outstanding as of January 12, 2021.
from January 1, 2020 to December 31, 2020
December 2020 private placement
Alpha financing and conversion of Alpha Note, including Palladium shares
Conversion of Series B preferred stock to common stock
September 2020 private placement
Acquisition of Tikkun Pharma IP
Exchange of warrants for common shares
Conversion of related party advance and notes payable
Common stock issued for accounts payable
Common stock issued in conjunction with note payable modification
Merger with Ameri Holdings, Inc.
From December 31, 2019 to August 11, 2020
Shares Issued for Extinguishment of liability
Rights Issue of Shares
1.Common stock offered 373,766 shares.
From December 31, 2019 to June 30, 2020
Shares Issued for Extinguishment of liability
Rights Issue of Shares
1.Common stock offered 862,500 shares.
From December 31, 2019 to March 31, 2020
Shares Issued for Extinguishment of liability
Conversion of accrued Interest
From December 31, 2018 to December 31, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A&B)
Shares issued for Fraction shares on reverse split
Preferred stock issued
On November 8, 2019, a majority of the company’s stockholders approved giving the Board discretionary authority to enact the reverse stock split. The Board approved the reverse stock split on a one for twenty-five ratio on November 21, 2019.
from June 30, 2019 to September 30, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A&B)
Preferred stock issued
From December 31, 2018 to June 30, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A)
Preferred stock issued
from December 31, 2018 to March 31, 2019
Shares Issued towards earnouts
Exercise of Warrants (PIPE series A)
from December 31, 2017 to December 31, 2018
Shares issued towards private placement
Exercise of warrants
Shares Issued towards earn-outs
Compensation to Directors
Compensation on seperation
Shares issued against preference dividend
Shares issued as acquisition consideration
from December 31, 2016 to December 31, 2017
Shares issued against services
Shares issued as acquisition consideration (ATCG)
Exercise and acceleration of RSU’s
Bonus shares issued to employees and Directors
Shares Issued towards earn-outs
Cashless exercise of warrants
Public offering of shares
Shares issued against preference dividend
1.Common stock offered by us 1,475,000 shares
2.Based on 15,856,249 shares outstanding on November 10, 2017